SHIP (Selinexor in Hormone Insensitive Prostate Cancer)

Summary

This is an open-label, Phase 2 clinical study of the oral Selective Inhibitor of Nuclear Export (SINE) selinexor (KPT-330) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Timeline

Start

2014-05

Primary completion

2016-04-01

Completion

2016-04-01

Outcome

Outcome not reported

Stopped (Enrollment): “Due to enrollment challenges. The termination is not a consequence of any safety concern.”

Drugs

Indications